黄园教授(博士生导师)
单位：四川大学华西药学院药剂系
通讯地址：成都市人民南路三段17号四川大学华西药学院
E-mail: hyuan@aliyun.com
简历
1989-1993 华西医科大学药学院，获理学学士学位
1993-1996 华西医科大学药学院，获药剂学硕士学位
2000-2003 四川大学华西药学院，获药剂学博士学位
1996- 四川大学华西药学院药剂系任助教、讲师、副教授、教授
2001-2002 美国马里兰大学药学院药剂学教研室访问学者
任职及学术兼职
全国药学专业学位研究生教育指导委员会委员。担任"Asian J. Pharm."杂志副主编和"药学学报"杂志编委，人卫社《临床药剂学》主编，人卫社《药剂学》副主编，中国医药出版社《药剂学》副主编。
研究方向
1、靶向给药系统的构建及其作用机制研究：包括生物大分子药物黏膜递药系统的研究；亚细胞靶向递药系统的研究
2、药物新剂型、新制剂的研究
主要研究课题
1.胰腺靶向口服递药系统的构建及其用于急性胰腺炎的生物治疗。国家自然科学基金重点项目，编号：32630056，起止日期：2027.1-2031.12，负责人。
2.基于“表面性质-主动靶向”交互作用的多肽蛋白类药物递送系统的跨黏膜转运调控。国家自然科学基金区域创新发展联合基金，编号：U22A20356，起止日期：2023.1-2026.12，负责人。
3.模拟肠道营养物质吸收的口服高效递药系统的研究。国家重点研发计划中国和新西兰政府间国际科技创新合作项目，编号：2021YFE0115200，起止日期：2022.1-2024.12，负责人。
4.克服组织和细胞屏障的高效递药系统的构建与机制研究。国家自然科学基金杰出青年基金，编号：81625023，起止日期：2017.1-2021.12，负责人。
获奖情况
静脉注射用脂质类纳米药物制剂关键技术及产业化。国家科学技术进步二等奖。2021，排名第六。
胞内递释制剂研发和规模化生产的关键技术。四川省技术发明奖一等奖。2024，排名第一。
多肽蛋白类药物口服高效递释系统基础研究。教育部高等学校自然科学一等奖。2019，排名第一。
入选国家高层次人才计划，2018
四川省学术技术带头人，2023
四川省三八红旗手标兵，2022
四川大学 "探究式-小班化"教学质量优秀奖
四川大学第五届“德沃群芳”育人文化建设优秀团队，2019
近年代表性论著
1.Jiawei Wu, Mingjie Ni, Liyun Xing, Yating Wang, Xi Liu, Yaxian Zheng, Lian Li,Yuan Huang*. Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis. Nature Communications,2026, 17, 2497.
2.Yudi Deng, Yunhui Zhang, Fuya Jia, Peihang Jiang , Lian Li*,Yuan Huang*. Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy.Science Advances.2026,12, 7150.
3.Liyun Xing, Qiuyue Liu, Jing Tao, Mingjie Ni, Xi Liu,Yuan Huang*. Dual-Scale Targeting of Myofibroblasts and Mitochondria via Oral Cascade Delivery Systems Alleviate Intestinal Fibrosis.Advanced Functional Materials,2026, 36, e29544.
4.Fuya Jia, Yudi Deng, Yiwen Xu, Jiahui Wu, Sijie Liu,Yuan Huang*. Biomimetic mitochondria-targeted drug delivery system for the treatment of inflammatory bowel disease.Journal of Controlled Release, 2026, 395, 114927.
5.Peihang Jiang, Fangyang Huang, Liqiang Chen, Hao Zhou, Yudi Deng, Lian Li, Mao Chen, andYuan Huang*. Intercellular NETwork-facilitated sarcoplasmic reticulum targeting for myocardial ischemia-reperfusion injury treatment.Science Advances, 2025, 11(7): adr4333.
6.Fuya Jia, Xiaoxing Fan, Licheng Wu, Yating Wang, Jisen Zhang, Zhou Zhou, Lian Li, Jingyuan Wen, andYuan Huang*. Enhanced lymphatic transportation of SLN by mimicking oligopeptide transportation route.Asian Journal of Pharmaceutical Sciences, 2025, 20(3): 101019.
7.Sa Chen, Aijia Wu, Xinran Shen, Jinxia Kong, andYuan Huang*. Disrupting the Dangerous Alliance: Dual Anti-Inflammatory and Anticoagulant Strategy Targets Platelet-Neutrophil Crosstalk in Sepsis.Journal of Controlled Release, 2025, 379: 814-831.
8.Xi Liu, Lie Zhang, Sa Li, Liyun Xing, Mingjie Ni, Minyi Huang, andYuan Huang*. Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics.ACS Nano, 2025, 19(24): 22357-22375.
9.Jinxia Kong, Yudi Deng, Yiwen Xu, Ping Zhang, Lian Li, andYuan Huang*. A Two-Pronged Delivery Strategy Disrupting Positive Feedback Loop of Neutrophil Extracellular Traps for Metastasis Suppression.ACS Nano, 2024, 18(24): 15432-15451.
10.Liyun Xing, Xi Liu, Licheng Wu, Jiawei Wu, Yudi Deng, Qiuyi Li, Zhou Zhou, Lian Li, andYuan Huang*. Orally Hierarchical Targeting Delivery Systems Relieve Colitis by Protecting Host Mitochondria and Modulating Gut Microbiota.Nano Today, 2024, 55: 102155.
11.Qingting Zuo, Jiayan Lyu, Xinran Shen, Fengju Wang, Liyun Xing, Minglu Zhou, Zhou Zhou, Lian Li, andYuan Huang*. A Less-is-More Strategy for Mitochondria-Targeted Photodynamic Therapy of Rheumatoid Arthritis.Small, 2024, 20(25): 2307261.
12.Xin Xiao, Lie Zhang, Mingjie Ni, Xi Liu, Liyun Xing, Licheng Wu, Zhou Zhou, Lian Li, Jingyuan Wen, andYuan Huang*. Enhanced Oral and Pulmonary Delivery of Biomacromolecules via Amplified Transporter Targeting.Journal of Controlled Release, 2024, 370: 152-167.
13.Xinran Shen, Yudi Deng, Liqiang Chen, Chendong Liu, Lian Li, andYuan Huang*. Modulation of Autophagy Direction to Enhance Antitumor Effect of Endoplasmic-Reticulum-Targeted Therapy: Left or Right?Advanced Science, 2023, 10(23): e2301434.
14.Yinglan Yu, Xinran Shen, Xin Xiao, Lian Li, andYuan Huang*. Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy.Small, 2023, 19(36): e2301149.
15.Yudi Deng, Fuya Jia, Peihang Jiang, Liqiang Chen, Liyun Xing, Xinran Shen, Lian Li, andYuan Huang*. Biomimetic Nanoparticle Synchronizing Pyroptosis Induction and Mitophagy Inhibition for Anti-Tumor Therapy.Biomaterials, 2023, 301: 122293.
16.Yuting Li, Liyun Xing, Lingling Wang, Xi Liu, Licheng Wu, Mingjie Ni, Zhou Zhou, Lian Li, Xiuxiu Liu, andYuan Huang*. Milk-Derived Exosomes as a Promising Vehicle for Oral Delivery of Hydrophilic Biomacromolecule Drugs.Asian Journal of Pharmaceutical Sciences, 2023, 18: 100797.
17.Liqiang Chen, Peihang Jiang, Xinran Shen, Jiayan Lyu, Chendong Liu, Lian Li, and Yuan Huang*. Cascade Delivery to Golgi Apparatus and On-Site Formation of Subcellular Drug Reservoir for Cancer Metastasis Suppression.Small, 2023, 19(11): 2204747.
18.Yinglan Yu, Shujie Li, Yuan Yao, Xinran Shen, Lian Li, and Yuan Huang*. Increasing Stiffness Promotes Pulmonary Retention of Ligand-Directed Dexamethasone-Loaded Nanoparticle for Enhanced Acute Lung Inflammation Therapy.Bioactive Materials, 2023, 20: 539-547.
19.Jiawei Wu, Liyun Xing, Yaxian Zheng, Yinglan Yu, Ruinan Wu, Xi Liu, Lian Li,Yuan Huang*. Disease-Specific Protein Corona Formed in Pathological Intestine Enhances the Oral Absorption of Nanoparticles.Acta Pharmaceutica Sinica B, 2023, 13(9): 3876-3891.
20.Qiuyi Li, Cheng Chen, Jinxia Kong, Lian Li, Junlin Li,Yuan Huang*. Stimuli-Responsive Nano Vehicle Enhances Cancer Immunotherapy by Coordinating Mitochondria-Targeted Immunogenic Cell Death and PD-L1 Blockade.Acta Pharmaceutica Sinica B,2022: 2533-2549
21.ChendongLiu,LianLi,JiayanLyu,YuchengXiang,LiqiangChen,ZhouZhou,Yuan Huang*.Split Bullets Loaded Nanoparticles for Amplified Immunotherapy.Journal of Controlled Release, 2022: 199-210
22.Lei Wu#, Lingling Wang#, Xi Liu, YuliBai, Ruinan Wu, Xiang Li, Yutong Mao, Ling Zhang, YongxiangZheng, Tao Gong, Zhirong Zhang andYuan Huang*. Milk-Derived Exosomes Exhibit Versatile Effects for Improved Oral Drug Delivery.Acta Pharmaceutica Sinica B, 2022:2029-2042
23.Shujie Li, Lian Li, Xi Lin, Cheng Chen, ChaohuiLuo, andYuan Huang*. Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis.ACS Nano,2022: 50-67
24.Junlin Li, Ping Zhang, Minglu Zhou, Chendong Liu,Yuan Huang*, Lian Li*.Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Postoperative Suppression of Cancer Metastasis.ACS Nano, 2022: 6064-6079
25.Yinglan Yu, LiYun Xing, Lian Li, Jiawei Wu, Jinhan He,Yuan Huang*. Coordination of rigidity modulation and targeting ligand modification on orally-delivered nanoparticles for the treatment of liver fibrosis.Journal of Controlled Release, 2022: 215-226
26.Xiaoli Yi, Yue Yan, Lian Li, Rui Zhou, Xinran Shen,Yuan Huang*. Combination of mitochondria impairment and inflammation blockade to combat metastasis.Journal of Controlled Release, 2022: 753-768
27.Minglu Zhou, Chaohui Luo, Zhou Zhou, Lian Li*,Yuan Huang*. Improving anti-PD-L1 therapy in triple negative breast Cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.Journal of Controlled Release,2021: 248-262
28.Liqiang Chen, Chendong Liu, Yucheng Xiang, JiayanLyu, Zhou Zhou, Tao Gong, Huile Gao, Lian Li*,Yuan Huang*. Exocytosis Blockade of Endoplasmic Reticulum-Targeted Nanoparticle Enhances Immunotherapy.Nano Today,2021:101356
29.Yucheng Xiang, Liqiang Chen, Chendong Liu, Xiaoli Yi,Lian Li*,Yuan Huang*. Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy.Small, 2021: 2104591
30.Xiaoli Yi, Yue Yan, Lian Li, Qiuyi Li, Yucheng Xiang,Yuan Huang*. Sequentially Targeting Cancer-Associated Fibroblast and Mitochondria Alleviates Tumor Hypoxia and Inhibits Cancer Metastasis by Preventing “Soil” Formation and “Seed” Dissemination.Advanced Functional Materials, 2021: 2010283.
